Current Report Filing (8-k)
March 06 2020 - 8:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 6, 2020 (March 2, 2020)
MYOS
RENS TECHNOLOGY INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-53298
|
|
90-0772394
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
45
Horsehill Road,
Suite
106 Cedar Knolls, New Jersey
|
|
07927
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrant's
telephone number, including area code: (973) 509-0444
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, par value $0.001 Series A Preferred Stock Purchase Rights, $0.001 par value
|
|
MYOS
|
|
The Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement.
On
March 2, 2020, MYOS RENS Technology Inc. (the “Company”) entered into securities purchase agreements (collectively,
the “Agreement”) with a group of accredited investors (the “Investors”) providing for the
issuance and sale by the Company of shares of the Company’s common stock, $0.001 par value, at a purchase price of $1.21
per share, the closing price of the common stock on the Nasdaq Capital Market on such date (the “Private Placement”). In
the Private Placement, the Company issued 1,533,058 shares of common stock to the Investors, including four members of the Company’s
board of directors, for aggregate gross proceeds of $1,855,000, which includes the conversion of $825,000 of the principal amount
of a promissory note previously issued by the Company to its chief executive officer. The Company intends to use the net proceeds
from the Private Placement primarily for working capital, research and development and other general corporate purposes. The closing
of the Private Placement occurred on March 5, 2020.
The
Agreement provides that the Company will use its commercially reasonable efforts to file a registration statement with the Securities
and Exchange Commission within 45 days from the closing of the Private Placement with respect to the re-sale of the shares issued
in the Private Placement and will use its commercially reasonable efforts to obtain effectiveness of the registration statement
within 90 days of the closing of the Private Placement. The Agreement also contains customary representations and warranties by
the Company.
The
foregoing description of the Agreement is qualified in its entirety by reference to the complete text of the Agreement, filed
hereto as Exhibit 10.1.
Item
3.02. Unregistered Sales of Equity Securities
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.
The
securities issued in the Private Placement as described above have not been registered under the Securities Act of 1933, as amended
(the “Securities Act”), and such issuances were made pursuant to the exemptions from registration provided
by Section 4 (a)(2) of the Securities Act and/or Regulation D promulgated thereunder.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MYOS RENS TECHNOLOGY, INC.
|
|
|
|
Dated: March 6, 2020
|
By:
|
/s/
Joseph Mannello
|
|
Name:
|
Joseph Mannello
|
|
Title:
|
Chief Executive Officer
|
2
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Apr 2023 to Apr 2024